Milena de Souza Vasconcelos, Anita L R Saldanha, Danielle Leão Cordeiro de Faria, Natália Rodrigues Dan-iel, Dino Martini Filho, Ana Paula Pantoja Margeotto, André Luis Valera Gasparoto, Paulo MaurÃÂcio Garcia Nosé, Giulia Mitsuko Schmit Hatae, Tania Leme da Rocha Martinez,
Atypical Hemolytic Uremic Syndrome (AHUS) is a syndrome of rare incidence, approximately 0.5 per million per year, of genetic characteristic, being inherited or acquired. Mutations occur in the proteins that regulate the complement system, predominantly factor H. The reported case is a female patient, without comorbidities and without family history of autoimmune disease. At the age of 16, she started with the flu (fever, oropharyngeal pain, runny nose) and was submitted to NSAIDs and Amoxicillin to control the condition, with a significant evolution of symptoms. After seven days of remission of the flu, she presented generalized malaise, nausea and vomiting, and it was necessary to go to the emergency room. Hemodialysis was initially indicated, which is why the patient underwent two hemodialysis sessions in this hospital and, subsequently, three days after her admission, she was transferred to Hospital Beneficência Portuguesa de São Paulo (05/09/2019). There are no reports by the patient of weight loss, adenomegaly, neurological symptoms and/or bleeding. In the absence of the result of the ADAMS 13 test, it was decided to request the medication Eculizumab, which was released with 13 days of hospitalization by the health plan. About Eculizumab: medication of choice for the treatment of aHUS. Eculizumab is a humanized anti-C5 monoclonal antibody (Eculizumab), terminal complement inhibitor. This antibody binds specifically and with high activity to the human complement protein C5, inhibiting its cleavage into C5a and C5b and preventing the generation of the terminal complement membrane attack complex (C5b-9)